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Summary
This review considers, in the context of British Skin Foundation (BSF)-funded
translational research into atopic eczema conducted in Newcastle, the complex
interactions between clinical and non-clinical scientists in both academia and
industry and how this may have impacted on clinical care. However, research in
individual centres does not occur in isolation and clinically relevant outcomes
from collaborative research are increasingly supported through regional and
national networks. This is illustrated by our trial of azathioprine in adults with
atopic eczema conducted across centres in the North East of England that
employed pharmacogenetic dosimetry. Correspondingly the formation of a UK
Translational Network for Translational Research in Dermatology (UK TREND)
has facilitated the development of a UK-wide network to support atopic eczema
projects based on an e-Delphi prioritisation exercise.
What’s already known about this topic?
• Atopic eczema is a disabling long-term skin condition that profoundly impacts on
patients and their families.
• Ciclosporin remains the only licenced systemic treatment for moderate-to-severe
atopic eczema in adults.
What does this study add?
• Translational research is not linear but represents a complex multi-disciplinary reci-
procal interaction across the clinical/non-clinical science interface.
• Investigator-initiated clinical trials in atopic eczema funded by the BSF have influ-
enced national/international guidelines and clinical practice and for the benefit of
patients.
• Pharmacogenetic dosimetry for azathioprine is now embedded in dermatological
clinical practice.
The Dermatology Research Group in Newcastle places the
highest possible priority on the translation of discovery
science for the benefit of all users (patients, the NHS, indus-
try, and policy makers) which is in close alignment with the
British Skin Foundation’s (BSF) strategic aims to further
understand the different types of skin disease and to identify
better and more effective treatments. We are also strongly
committed to increasing public and patient awareness about
the impact of disabling skin disease and promoting interaction
and education outside of the routine clinical care setting.
In this review, we will consider the outcomes from some of the
BSF-funded research related to atopic eczema conducted in
Newcastle and the impact on patient care and future research.
Evidence-based treatments for atopic eczema
Atopic eczema is a disabling long-term skin condition that has
a profound negative impact on patients and their families and
therapeutic options for moderate-to-severe disease remain lim-
ited. Although onset is usually in early childhood, atopic
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eczema may persist (particularly in more severe cases) or
recur during adulthood where a prevalence of ~3–10%1,2 is
reported. A significant percentage of adult patients have resis-
tant disease that can significantly impair quality of life. Refrac-
tory moderate-to-severe atopic eczema in adults usually runs a
prolonged and protracted course3 and the unpredictable nature
of disease flares is particularly troublesome.4 The mainstay of
treatment remains topical steroids and moisturisers. In 2000
an independent systematic review5 highlighted the lack of
therapeutic options for patients with atopic eczema not ade-
quately controlled by optimised topical treatments and under-
scored the need for scientifically robust testing of a range of
treatments for the disease. Indeed, there remains just one oral
drug with a product license for moderate-to-severe atopic
eczema, ciclosporin. Furthermore, the British National Formu-
lary recommends that treatment duration with cicloporin
should be limited period for a maximum period of 2 months
maximum in part because prolonged use of the drug is associ-
ated with hypertension, renal impairment and risk of can-
cer.6,7,8,9 A robust evidence base supporting other treatment
options for refractory moderate-to-severe atopic eczema was
therefore needed.
Following an open pilot study in 2001,10 Reynolds and
Meggitt, with grant support from the BSF and the Wellcome
Trust, led a regional (North East of England) multi-center
placebo-controlled randomised controlled trial of azathioprine
in adult patients with moderate-to-severe atopic eczema. This
was the first parallel-group randomised controlled trial of
azathioprine for atopic eczema and the first trial for a der-
matological condition to utilize a stratified medicine
approach in which dosing was tailored to patients based on
their genetically-determined ability to metabolise the drug
(as determined by thiopurine methyltransferase [TPMT]
activity). The results were published in the Lancet in 200611
and formed the basis of Dr Meggitt’s MD thesis (awarded
with Distinction). Azathioprine significantly improved disease
activity – six area, six sign atopic dermatitis (SASSAD) sever-
ity score, the primary endpoint, by 37% (compared to a
20% reduction in the placebo group) as well as body area
affected (by 26% compared to 15% by placebo). Impor-
tantly, objective improvements in disease activity were
matched by improvements in patient-oriented symptoms and
quality of life scores. For example, itch scores reduced sig-
nificantly (by 46%) in patients who received azathioprine
compared to those who received placebo. In 2007, Dr Meg-
gitt also received the British Skin Foundation Award for Best
Research Project funded in last 10 years.
The evidence from this study11 and a placebo-controlled
cross over trial of azathioprine, also conducted in the UK,12
has underpinned recommendations in UK13 and European
guidelines14,15,16 on disease treatment, and azathioprine is
now in widespread use in the UK. For example, evidence
from a 2013 survey of UK dermatologists conducted through
the UK Translational Research Network in Dermatology (UK
TREND) and the UK Dermatology Clinical Trials Network (UK
DCTN), indicated that azathioprine has been widely adopted
in the UK as a treatment of refractory atopic eczema.17 Sys-
temic therapy was the most popular second-line treatment
option, chosen by 49% of respondents, and it was also the
second most popular first-line treatment option (after
phototherapy), chosen by 36% of respondents. Of those con-
sidering systemic therapy, azathioprine was the most popular
first-line choice of drug (46% of respondents). Furthermore,
there were clear differences in the pattern of usage and the
relative duration of both average and maximum periods of
usage between systemic agents. Thus, for example, azathio-
prine treatment was continued on average, for 13.8 months
compared with 5.8 months for ciclosporin – the next most
commonly used drug. This may relate to longer-term control
of symptoms and a better safety profile than ciclosporin. In
addition, the reported maximum periods of usage indicated
that the majority of respondents considered azathioprine as a
longer-term (over 2 year) treatment or maintenance option.
Nevertheless, the BAD guidelines on azathioprine advise cau-
tion over the prolonged use of azathioprine in part because of
uncertainty over cancer risk13 and we generally discuss this
uncertainty with patients who continue on medication over
12 months.
Based on the reported numbers of patients treated by the
consultant dermatologists in the survey, we can estimate that
about 4900 patients begin treatment with azathioprine each
year in the UK. This compares to ~4450 commencing ciclo-
sporin and ~3950 commencing methotrexate and 7850 being
referred for narrow-band UVB phototherapy. Together this
represents a large proportion of the patient pool of adult
patients with refractory atopic eczema seen by consultant-level
dermatologists in the UK.
In a previous study in which we compared narrowband
UVB phototherapy to UVA phototherapy to placebo,18 we
had analysed clinical response using a summary measure
methodology, as proposed by Matthews.19,20 We also applied
this methodology to the study of azathioprine in atopic
eczema. This method takes into account the variability of dis-
ease activity over time and by utilising a series of measure-
ments, during a defined period, provides a more
representative summary of response than simply using two
measurements at the start and end of a defined period. The
variability of baseline measurements is illustrated by patient F
(Fig. 1) who was treated with placebo during the trial. The
majority of responses were well represented by a linear
regression line as shown by patient F (Fig. 1) who later
received azathioprine following completion of the study
(Meggitt & Reynolds, unpubl. data). Another interesting
observation was that in general the pattern of response
within individual patients appeared similar upon retreatment
as illustrated by patients N and C (Fig. 2).
A full entry on azathioprine appeared for the first time in
the skin section of the British National Formulary (a standard
resource consulted by UK clinicians when deciding which
drug to prescribe) in March 2010. This entry provides further
evidence of research impact and states that azathioprine should
be considered for severe refractory eczema.
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Pharmacogenetic dosimetry
As illustrated in Figure 3, azathioprine is a pro drug that is
rapidly metabolised to 6-mercaptopurine (6-MP). 6-MP is
itself subject to metabolism by several competing pathways
that result in a conversion to either inactive metabolites or
bioactivation to 6-thioguanine nucleotides (6-TGN). 6-TGNs
mediate the therapeutic activity but are also responsible for
specific side effects including bone marrow suppression. Thus
the balance between enzyme inactivation and activation is crit-
ical for optimal therapeutic activity. TPMT metabolises azathio-
prine (and similar drugs) and genetic variants within the
population result in differential ability to break down the
drug. Thus, for example, absent TPMT activity (TPMTLL) may
result in high toxic levels of 6-TGNs and is a contraindication
to azathioprine therapy. Further, evidence supports a lower
starting dose of azathioprine in patients with intermediate
TPMT activity (TPMTHL). The dosing guidance within the
BNF–1–3 mg/kg/day for normal/high TPMT activity
(TPMTHH), 0.5–1 mg/kg/day for low/intermediate TPMT
activity (TPMTHL). –reflects the doses used in our published
trial (2.5 and 1 mg/kg/day respectively).
In line with the concept of pharmacogenetic dosing, almost
95% of respondents from our 2013 survey17 agreed/strongly
agreed that TPMT level at baseline should guide choice of ini-
tial dose. These data are consistent with an earlier survey of
UK consultant which showed a high level of uptake of TPMT
enzyme-level testing by dermatologists (94%), compared with
gastroenterologists (60%) and rheumatologists (47%), prior to
prescribing azathioprine.21
A number of studies particularly in inflammatory bowel
have demonstrated a correlation between TGN levels and ther-
apeutic efficacy. For example, a therapeutic range of 235–
450 pmols/8 9 108 red blood cells has been proposed22 and
optimization of azathioprine dosimetry on the basis of mea-
suring metabolite levels has led to improved outcomes.23 Sys-
tematic studies correlating TGN levels with therapeutic efficacy
in dermatology are limited although one study has suggested
a slightly lower therapeutic threshold of 179 pmol/8 9 108
red blood cells.24 However, our unpublished experience in
individual cases suggest potential utility with measuring TGN
levels particularly in patients with heterozygote TPMT activity.
This is illustrated in Figure 4. The therapeutic regime based
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Figure 1. Summary measure of clinical response. Regression lines
were fitted to the data points of eczema disease activity (SASSAD) over
the 12 weeks of treatment.
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Figure 2. Summary measure of clinical response. Regression lines,
fitted to the data points of eczema disease activity (SASSAD) over the
treatment period, show a similar slope on repeat courses.
Figure 3. Simplified schematic diagram illustrating metabolism of
azathioprine. The pro-drug azathioprine is converted to 6-MP with
subsequent metabolism to active metabolites 6-thoiguanine
nucleotides (6-TGNs). Methylation of several thiopurine intermediates
by TPMT is important in diverting metabolism away from production
of 6-TGNs. Inhibition of xanthine oxidase by allopurinol may also
lead to an increase in 6-TGNs, hence allopurinol should in general be
avoided in patients receiving azathioprine.
Figure 4. Correlation of clinical response and serum concentrations
6-thoiguanine nucleotides (6-TGNs). No clinical response during
1st course with low therapeutic TGN levels but clinical improvement
during 2nd course following medication of azathioprine dosage regime
and achievement of therapeutic 6-TGN levels.
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on TPMT status, as described in the Lancet paper, was used in
a TPMT heterozygote patient during the first course of treat-
ment (Fig. 4). Although treatment was well tolerated, the
patient showed no therapeutic response and TGN levels
remained <70 pmols/8 9 108 red blood cells. Consequently
during a second course, the lower dose initiation phase was
omitted and TGN levels within the nominal therapeutic range
were achieved. This correlated with an improved clinical
response (Fig. 4). Of course, such data on individual patients
should be interpreted with caution but we are now utilising
measurement of TGN levels in clinical practice under such cir-
cumstances. On the other hand, a study of 12 children treated
with azathioprine showed no obvious correlation between
TGN levels and clinical response25 although children generally
show lower 6-TGN concentrations compared to adults.26
Mechanism of action of systemic therapies in
atopic eczema
Although recent research has provided significant insight into
the molecular genetics and pathogenesis of atopic eczema, the
mechanism of therapies that are effective in this disease
remains incompletely understood. Interestingly, genetic studies
provide evidence of distinct genetic loci for atopic eczema and
psoriasis and where loci are shared the effect appears to be in
the opposite direction for the two diseases.27 On the other
hand, a number of therapies including topical calcineurin
inhibitors, narrow-band UVB phototherapy and systemic
agents such as ciclosporin and methotrexate are effective for
both psoriasis and atopic eczema.
Ciclosporin and cyclophilins
To gain insight into the mechanisms involved in the resolu-
tion of atopic eczema we studied the action of ciclosporin as
it is one of the most effective systemic agents currently avail-
able and has a rapid onset of action. Gaining insight into its
mechanism(s) of action in atopic eczema may identify novel
therapeutic targets. This would have clinical relevance as
ciclosporin usage for atopic eczema is generally limited to
short courses due to its potential side-effects.
Given that the pathogenesis of atopic eczema involves a com-
plex interplay between barrier dysfunction and immune activa-
tion and that filaggrin mutations remain the most common
genetic risk factor for atopic eczema, we were interested to
explore direct effects of ciclosporin and epidermal ker-
atinocytes. The highly conserved family of cyclophilin proteins,
characterized by peptidyl-prolyl cis-trans isomerase activity,
were first identified as binding partners for ciclosporin.
Although the interaction between the ciclosporin/cyclophilin A
complex, calcineurin and NFAT transcription factors is crucial
to inhibition of T cell activation, cyclophilins are ubiquitously
expressed. In an earlier study, supported by the BSF, we showed
that cyclophilin B (CypB), an endoplasmic reticulum (ER)-resi-
dent protein, is secreted by keratinocytes in response to phar-
macologically relevant concentrations of ciclosporin.28
Moreover, a key residue within the ciclosporin-binding site of
CypB controlled the secretion of CypB.28 These findings may be
relevant to the action of ciclosporin in atopic eczema because
CypB is known to induce chemotaxis of inflammatory cells and
keratinocytes themselves express CypB (CD147) receptors.
To further understand the physiological role of CypB in
human keratinocytes, we overexpressed wild type CypB (CypB
WT) and a mutant protein that is effectively unable to bind
ciclosporin (CypBW128A). Interestingly, we showed that both
CypB WT and CypBW128A increased the proliferative capacity of
keratinocytes in both monolayer and in 3-D skin equiva-
lents.29 We also showed that CypB positively regulated ker-
atinocyte differentiation. To understand the relevance of these
findings to atopic eczema we studied biopsies taken from
lesional atopic eczema skin at baseline and during the early
phases of treatment with ciclosporin. Our results show that
(1) keratinocyte differentiation was induced early during
ciclosporin therapy and (2) CypB expression was modulated
in a proportion of subjects. Together these data provide evi-
dence for a direct interaction of ciclosporin with CypB in epi-
dermal keratinocytes which may contribute to the therapeutic
effects of ciclosporin in atopic eczema. Further studies to
investigate ciclosporin analogues that show relative specificity
for CypB appear warranted.
Methotrexate
Following on from these studies, through a BBSRC-CASE stu-
dentship with Stiefel, GSK we have investigated pathophysio-
logical mechanisms of atopic eczema and the mechanism of
action of methotrexate. Interestingly, preliminary results of
proteomic studies following knock-down of filaggrin in epi-
dermal equivalents (to mimic the effects of filaggrin deficiency
in atopic eczema skin) identified a number of differentially
expressed proteins that included cyclophilin A, further under-
scoring a potential role for cyclophilins in atopic eczema
pathogenesis.30 Moreover, our early studies of methotrexate in
skin equivalents showed a positive effect on late terminal dif-
ferentiation in keratinocytes, emphasizing the relevance of the
epidermal barrier as a therapeutic target.31
UK TREND
Taking advantage of the collaborative nature of UK dermatol-
ogy, and building on the success of established networks
including BADBIR and the UK DCTN, we have recently estab-
lished UK TREND. Based on an e-Delphi prioritisation exer-
cise32 and unmet need, UK TREND has focused on developing
two networks to support translational research. One of these is
centered on atopic eczema. Following two meetings of the
atopic eczema network, three sub-themes emerged that are
now being further developed. These are: (1) a longitudinal
cohort study of photo and systemic therapy; (2) gene-envir-
onment interactions and (3) stratified medicine. We hope that
together the network can take forward research in this area
for the future benefit of patients and their families.
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In summary, BSF-funded research in Newcastle has provided
insight into pathophysiological mechanisms in atopic eczema,
as well as the pharmacology and pharmacogenetics of systemic
therapeutic agents. These findings have been translated into
improved patient care. In part through the support of individ-
ual research careers and support nationally for organisations
such as UK TREND, we are now poised to further advance
understanding of atopic eczema with the real prospect of per-
sonalized therapeutics in this disabling long-term condition.
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